Rhenman & Partners Asset Management AB Acquires 290,000 Shares of Vera Therapeutics, Inc. $VERA

Posted by Brian Himes on Jun 13th, 2026

Rhenman & Partners Asset Management AB increased its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 223.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 420,000 shares of the company’s stock after purchasing an additional 290,000 shares during the period. Vera Therapeutics makes up 2.0% of Rhenman & Partners Asset Management AB’s portfolio, making the stock its 12th biggest position. Rhenman & Partners Asset Management AB’s holdings in Vera Therapeutics were worth $21,269,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of VERA. Vestal Point Capital LP lifted its holdings in shares of Vera Therapeutics by 24.0% during the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after purchasing an additional 600,000 shares in the last quarter. Integral Health Asset Management LLC lifted its stake in Vera Therapeutics by 47.8% in the 3rd quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock valued at $49,402,000 after acquiring an additional 550,000 shares in the last quarter. Braidwell LP acquired a new position in Vera Therapeutics during the 3rd quarter worth approximately $13,738,000. Armistice Capital LLC grew its stake in shares of Vera Therapeutics by 294.1% during the 3rd quarter. Armistice Capital LLC now owns 536,000 shares of the company’s stock worth $15,576,000 after acquiring an additional 400,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Vera Therapeutics by 11.9% during the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after acquiring an additional 379,748 shares in the last quarter. Institutional investors own 99.21% of the company’s stock.

Insider Activity

In other news, CEO Marshall Fordyce sold 18,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total transaction of $679,690.00. Following the sale, the chief executive officer owned 216,744 shares in the company, valued at $7,963,174.56. This represents a 7.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Evercore set a $91.00 price target on shares of Vera Therapeutics in a research note on Friday, May 15th. Jefferies Financial Group reaffirmed a “buy” rating and set a $60.00 price target on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. The Goldman Sachs Group reaffirmed a “buy” rating and set a $90.00 price target on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Vera Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $78.00.

View Our Latest Report on VERA

Vera Therapeutics Trading Up 1.8%

Shares of Vera Therapeutics stock opened at $34.26 on Friday. Vera Therapeutics, Inc. has a 12-month low of $19.07 and a 12-month high of $56.05. The stock has a market cap of $2.46 billion, a P/E ratio of -6.18 and a beta of 0.93. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. The business’s 50 day moving average is $37.02 and its 200-day moving average is $41.38.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period in the prior year, the company posted ($0.81) earnings per share. Equities research analysts predict that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current fiscal year.

About Vera Therapeutics

(Free Report)

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.